Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Adagene announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Related Keywords

San Francisco ,California ,United States ,Australia ,China ,Suzhou ,Jiangsu ,Japan ,Singapore ,American , ,Twitter ,Linkedin ,Nasdaq ,Dynamic Precision Library ,Adagene Inc ,American Society Of Clinical Oncology ,European Union ,Exchange Commission ,American Society ,Clinical Oncology ,Cancers Symposium ,Media Contact ,Ami Knoefler ,Adagene ,Uzastotug ,Pembrolizumab ,Mss Crc ,Sco Gi Symposium ,